Progress Towards a Cure for Breast Cancer: Small Steps and Big Leaps
Wednesday, September 24
11:30 am to 12:30 pm CT
Presented by Dr. George Sledge | Professor of Medicine and Pathology, and Chief of the Division of Oncology in the Department of Medicine at Stanford University
Hosted by the North Central Region of Susan G. Komen
While we are making real progress, the cure has been an elusive goal in breast cancer, particularly in the setting of advanced disease. Where are we today, and where are we headed in the near future? How can we use the emerging technologies of genomics and tumor immunology to improve the lot of breast cancer patients? And what is Susan G. Komen’s role in the emerging biologic revolution that will transform breast cancer care?
Dr. George Sledge
Dr. Sledge is recognized internationally for his work in breast cancer research and treatment. A clinical trialist and pioneer in the development of novel therapies for breast cancer, Dr. Sledge directed the first large, nationwide trial that studied the efficacy of paclitaxel as a therapy for advanced breast cancer. Since then, he has served as the principal investigator for many nationwide clinical trials involving new therapies for breast cancer. His research focuses on molecular and tumor biology, growth factors and anti-angiogenic therapy. With his Komen-funded grant, Dr. Sledge is searching for new, druggable targets in triple negative breast cancers, investigating the process of angiogenesis (tumors forming new blood vessels) and identifying genetic clues that will help us better understand how this occurs. He is also evaluating new technologies that capture tumor cells circulating in the blood stream, which may provide doctors with better tools to understand and treat metastatic breast cancer.
When asked about his partnership as a Komen Grantee, Dr. Sledge replied: “Komen’s role is not just at a funder of research, but as a convener of researchers. We bring researchers together at our Scientific Advisory Board, at our Komen Scholars meeting, in our study sections that judge the merits of grants, and in the grant applications themselves. We are an eminently social organization: we actively create the “Great Weave” of breast cancer research. And that is why I love working with Susan G. Komen.”